Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Michael Daskalakis

24PUBLICATIONS
68CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Cardiovascular medicine and haematology not elsewhere classifiedHaematologyNanotoxicology, health and safetyElectrical energy generation (incl. renewables, excl. photovoltaics)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (24)

Sort by Publication Date:
|Jun 06, 2026
Impact of fludarabine dosage on outcomes in large B-cell lymphoma patients treated with CAR T-cell therapy: a retrospective study of the CTIWP of the EBMT.

|Feb 28, 2026
Can hyperleukocytosis be caused by a non-hematologic condition? A 10-year retrospective tertiary-care center cohort study.

Elisavet Moutzouri, Emmanuel Häfliger, Katarzyna Aleksandra Jalowiec

|Aug 28, 2025
Clonal Hematopoiesis and Outcomes After High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients with AML, Myeloma, and Lymphoma.

Corinne Natalie Schmid, Katharina Sponagel, Ulrike Bacher

|May 15, 2025
CAR-T cell manufacturing failures and out-of-specification products in the real-world setting: A survey from the EBMT cellular therapy and immunobiology working party.

Nina Worel, Jarl E Mooyaart, Jorinde D Hoogenboom

|Nov 15, 2024
Comparing stem cell mobilization with chemotherapy and cytokine (G-CSF) versus cytokine alone in myeloma patients (MOCCCA): a randomized phase II, open-label, non-inferiority trial.

Barbara Jeker, Laura Thalmann, Ulrike Bacher

|Aug 27, 2024
Choice of commercially available CAR-T cell products for r/r DLBCL & PMBCL in Europe: a survey on behalf of the cellular therapy & immunobiology working party (CTIWP) of the EBMT.

Urban Novak, Jarl E Mooyaart, Michael Daskalakis

Pageof 4

Frequent Collaborators

17 joint publications

Thomas Pabst

15 joint publications

Ulrike Bacher

6 joint publications

Katja Seipel

6 joint publications

Dilara Akhoundova

3 joint publications

Henning Nilius

3 joint publications

Jürgen Kuball

3 joint publications

Florent Malard

3 joint publications

Naomi Porret

3 joint publications

Gertrud Wiedemann

2 joint publications

Thilo Zander

Frequent Collaborators

17 joint publications

Thomas Pabst

15 joint publications

Ulrike Bacher

6 joint publications

Katja Seipel

6 joint publications

Dilara Akhoundova